Oxford Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Oxford Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,080	Closed	-$506K	–	2044
2018 Q4	$506K	Sell	1,080 -2,644	-71%	-$1.71M	0.01%	1195
2018 Q3	$3.21M	Buy	+3,724	New	+$2.69M	0.07%	407
2018 Q1	–	Sell	-1,222	Closed	-$561K	–	1929
2017 Q4	$561K	Buy	+1,222	New	+$557K	0.01%	1146

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Oxford Asset Management's TVRD Position: Q1 2019 in Review

Oxford Asset Management sold out of Tvardi Therapeutics (TVRD) in Q1 2019, closing a stake of 1,080 shares — an estimated $506K sold.

Oxford Asset Management first reported a position in TVRD in Q4 2017 and held it in 3 quarters. The position peaked at $3.21M in Q3 2018. 135 funds tracked by Wall St. Rank hold TVRD as of Q1 2019.

Oxford Asset Management reported no remaining Tvardi Therapeutics position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 1,080 Tvardi Therapeutics shares in Q1 2019, an estimated $506K.
Oxford Asset Management first reported a position in Tvardi Therapeutics in Q4 2017 and held it in 3 quarters.
Oxford Asset Management's Tvardi Therapeutics position peaked at $3.21M in Q3 2018.
135 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.